A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (PTS) with advanced or metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Maroun, Jean A. [1 ]
Jonker, Derek [1 ]
Goel, Rakesh [1 ]
Cripps, Christine [1 ]
Lister, Diane [1 ]
Chiritescu, Gabriela [1 ]
机构：
[1] Ottawa Hosp, Reg Canc Ctr, Ottawa, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [31] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST - LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Adda, B.
    Farida, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 73 - 73
  • [32] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST -LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, A.
    Smail, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 67 - 68
  • [33] A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer
    Maroun, Jean
    Marginean, Horia
    Jonker, Derek
    Cripps, Christine
    Goel, Rakesh
    Asmis, Timothy
    Goodwin, Rachel
    Chiritescu, Gabriela
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : E257 - E268
  • [34] Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
    Bazarbashi, Shouki
    Aljubran, Ali
    Alzahrani, Ahmad
    Mohieldin, Ahmed
    Soudy, Hussein
    Shoukri, Mohammed
    CANCER MEDICINE, 2015, 4 (10): : 1505 - 1513
  • [35] Phase II multicenter sequential study of oxaliplatin (O) and capecitabine (C) followed by irinotecan (I) and capecitabine (C) in first line advanced colorectal cancer (CRC).
    Cassinello, J
    Alvarez, JV
    García-López, MJ
    Pujol, E
    Colmenarejo, A
    de Segovia, F
    Marcos, F
    Filipovich, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 257S - 257S
  • [36] Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
    H Y Sheikh
    J W Valle
    K Palmer
    A Sjursen
    O Craven
    G Wilson
    R Swindell
    M P Saunders
    British Journal of Cancer, 2007, 96 : 38 - 43
  • [37] Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
    Sheikh, H. Y.
    Valle, J. W.
    Palmer, K.
    Sjursen, A.
    Craven, O.
    Wilson, G.
    Swindell, R.
    Saunders, M. P.
    BRITISH JOURNAL OF CANCER, 2007, 96 (01) : 38 - 43
  • [38] Combination chemotherapy with capecitabine (C), irinotecan (I), oxaliplatin (O), and bevacizumab (B; XELOXIRIA) as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a phase I-II trial.
    Bazarbashi, S.
    Aljubran, A. H.
    Soudy, H.
    Darwish, A.
    Eltigani, A.
    Nabil-Ahmed, M.
    Edesa, W.
    Almubarak, M.
    Abu Sabaa, A.
    Shoukri, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
    Zeuli, M
    Nardoni, C
    Pino, MS
    Gamucci, T
    Gabriele, A
    Ferraresi, V
    Giannarelli, D
    Cognetti, F
    ANNALS OF ONCOLOGY, 2003, 14 (09) : 1378 - 1382
  • [40] PHASE I/II TRIAL OF PERIOPERATIVE OXALIPLATIN (O), CAPECITABINE (C) AND IRINOTECAN (I) FOR PATIENTS (PTS) WITH LOCALLY ADVANCED GASTRIC CANCER
    Utelbayeva, A.
    Arzykulov, Z.
    Izhanov, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 45 - 46
12345